Compare AbbVie Inc (ABBV) vs Bank of New York Mellon Corp (BNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Bank of New York Mellon Corp — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while Bank of New York Mellon Corp trades at $149.51 (market cap $104.95B). The key difference: AbbVie Inc is far larger — about 4.3× Bank of New York Mellon Corp's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | BNY | |
|---|---|---|
Market Cap | $449.91B | $104.95B |
Sector | Health | Financials |
52-Week High | $261.07 | $152.91 |
52-Week Low | $184.85 | $92.69 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | 1.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
BNY Mellon stock trades at $152.91, up 4.29% on the day, near its consensus price target of $156. The stock shows strong momentum with three consecutive quarterly earnings beats and a bullish technical trend. Recent news highlights a planned 19% dividend increase to $0.63 per share and expansion into digital asset services, reflecting strategic growth initiatives. Revenue has grown steadily from $16.0B in 2022 to $19.8B in 2025, with net income margin improving to 29.21%.
The outlook remains positive with analyst consensus leaning toward 'Hold' but no 'Sell' ratings. Key opportunities include dividend growth and digital finance expansion, while risks involve high investing cash outflows and interest expense pressures. The stock's valuation at a P/E of 18.61 appears reasonable given profitability trends, but investors should monitor execution on capital investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →
